| |
Dr. h.c. Daniel
Vasella, MD Swiss,
age 50
Daniel Vasella graduated with a MD from the
University of Bern in 1979. After holding a number of medical positions
in Switzerland, he joined Sandoz Pharmaceuticals Corporation in the
US in 1988. From 1993 to 1995, Daniel Vasella advanced from Head of
Corporate Marketing and Senior Vice President and Head of Worldwide
Development to Chief Operating Officer of Sandoz Pharma Ltd. In 1995
and 1996, Daniel Vasella was a member of the Sandoz Group Executive
Committee and Chief Executive Officer of Sandoz Pharma Ltd. After
the merger that created Novartis in 1996, Daniel Vasella served as
President and Chief Executive Officer. In 1999, he additionally was
appointed Chairman of the Board of Directors. Daniel Vasella is also
a member of the Board of Directors of Pepsico, Inc., United State.
In addition, he is a member of the International Board of Governors
of the Peres Center for Peace in Israel and a member of several industry
associations and educational institutions, including the International
Business Leaders Advisory Council for the Mayor of Shanghai. In 2002,
Dr. Vasella was awarded an honorary doctorate by the University of
Basel.
Urs Baerlocher, JD Swiss,
age 61
Urs Baerlocher earned his JD at the University
of Basel and was admitted to the bar in 1970. After having worked
as a tax lawyer, he joined Sandoz in 1973, and held a number of key
positions including Head of Strategic Planning and Head of Group Reporting.
In 1987, he was made a member of the Sandoz Executive Board, responsible
i.a. for Strategic Planning, HR, Legal, Taxes, Patents and Trademarks.
In 1990, he became CEO of the Sandoz Nutrition Division and then,
in 1993, CEO of Sandoz Pharma. In 1995, Urs Baerlocher assumed the
position of Chairman of the Board of Sandoz Deutschland GmbH (Germany)
and Biochemie GmbH (Austria). After the formation of Novartis in 1996
he served as Head of International Coordination, Legal, Tax, Insurance,
before his responsibilities were widened to include Corporate Intellectual
Property, Corporate Health, Safety & Environment and Corporate Security.
Raymund Breu, PhD Swiss,
age 58
Raymund Breu graduated from the Swiss Federal
Institute of Technology (ETH) in Zurich, Switzerland, with a PhD in
mathematics. In 1975, he joined the Treasury Department of the Sandoz
Group, and, in 1982, became the Head of Finance for the Sandoz affiliates
in the UK. In 1985, he was appointed Chief Financial Officer of Sandoz
Corporation in New York, where he was responsible for all Sandoz Finance
activities in the US. In 1990, he became Group Treasurer of Sandoz
Ltd., Basel, Switzerland, and, in 1993, Head of Group Finance and
Member of the Sandoz Executive Board. Following the formation of Novartis
in 1996, he assumed his current position as Chief Financial Officer
and member of the Group Executive Committee. Raymund Breu is also
a member of the Board of Directors of Swiss Re, Chiron (USA) and of
the SWX Swiss Exchange and of its admission panel and its takeover
commission.
Paul Choffat, JD Swiss,
age 54
Paul Choffat holds a JD from the University
of Lausanne, Switzerland, and an MBA from the International Institute
for Management Development in Lausanne. He started his professional
career with Nestlé in Zurich, Switzerland, and London, UK. From 1981
to 1985, he was a project manager at McKinsey & Company in
|
|
Zurich. Between 1987 and 1994, he held a number
of leading positions at Landis & Gyr in Zug, Switzerland, where
he became a member of the Executive Board and Head of the Communications
Division. In 1994, he moved to Von Roll in Gerlafingen, Switzerland,
as CEO. Paul Choffat joined Sandoz in 1995 as Head of Management
Resources and International Coordination. He subsequently became
a member of the Executive Board and was responsible for Group Planning
and Organization. During the Novartis merger he headed the integration
office. In 1996, he returned to line management as CEO of Fotolabo
SA, Montpreveyres- sur-Lausanne, Switzerland, where he remained
for three years before becoming an entrepreneur and private investor
in 1999. He rejoined Novartis in January 2002 as Head of Novartis
Consumer Health and member of the Group Executive Committee.
Thomas Ebeling German,
age 44
Thomas Ebeling graduated from the University
of Hamburg with a degree in psychology. From 1987 to 1991, he held
several positions of increasing responsibility at Reemstma Germany.
In 1991, he joined Pepsi-Cola Germany as Marketing Director. He became
Marketing Director for Germany and Austria in 1993 and was National
Sales and Franchise Director for Pepsi’s retail and onpremise sales
from 1994. He then served as General Manager of Pepsi-Cola Germany.
In 1997, Thomas Ebeling joined Novartis as General Manager of Novartis
Nutrition for Germany and Austria. After having served as CEO of Novartis
Nutrition, he became CEO of Novartis Consumer Health worldwide, and
then Chief Operating Officer of Novartis Pharmaceuticals, before attaining
his present position in 2000.
Prof. Mark C. Fishman, MD American,
age 53
Mark C. Fishman is a graduate of Yale College
and Harvard Medical School. He completed his Internal Medicine residency,
Chief residency, and Cardiology training at the Massachusetts General
Hospital. He serves on several editorial boards and has worked with
national policy and scientific committees including those of the National
Institute of Health (NIH) and Wellcome Trust. He has been honored
with many awards and distinguished lectureships and is a Fellow of
the American Academy of Arts and Sciences. Before joining Novartis,
Mark C. Fishman was Professor of Medicine at Harvard Medical School
and Chief of Cardiology and Director of the Cardiovascular Research
Center at the Massachusetts General Hospital in Boston.
Juergen Brokatzky-Geiger, PhD German,
age 51
Juergen Brokatzky-Geiger graduated with a
PhD in Chemistry from the University of Freiburg, Germany, in 1982.
He joined Ciba-Geigy in 1983 as a Laboratory Head in the Pharmaceutical
Division. After a job rotation in Summit, NJ, from 1987 to 1988 he
held a number of positions of increasing responsibility, including
Group Leader of Processes in R&D, Head of Processes in R&D and Head
of Process Development and Pilot Plant Operations. During the merger
of Ciba- Geigy and Sandoz in 1996, Juergen Brokatzky-Geiger was appointed
Integration Officer of Technical Operations. Thereafter, he became
the Head of Chemical and Analytical Development and, from 1999 until
August 2003, he served as the Global Head of Technical R&D. Juergen
Brokatzky-Geiger was appointed to his present position as Head of
Human Resources on September 1, 2003. |
|
95